CGON
CG Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$61.65
−2.87%Year over year
Reported trailing growth
- Revenue
- +1030.3%
- EBITDA
- -55.9%
- EBIT
- -60.6%
- EPS
- -51.7%
- Free cash flow
- -90.7%
- Operating cash flow
- -90.2%
Forward estimates
Based on analyst estimates
- Revenue
- +764.6%
- EBITDA
- -34.2%
- EPS
- -26.1%
Three-year CAGR
- Revenue
- +176.6%
- EBITDA
- -81.3%
- EBIT
- -66.4%
- Net income
- -82.9%
- EPS
- -47.5%
- Free cash flow
- -67.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026